Trial reportPhytotherapy research : PTR2015
Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer.
Trial report in Phytotherapy research : PTR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- An Updated and Comprehensive Review ofMolecules (Basel, Switzerland) · 2026Review
- Exercise and Phellodendron amurense extract differentially impinge on oxidative stress response pathways in a mouse model of prostate cancer.Scientific reports · 2026Article
- Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancer.Cancer letters · 2024Article
- Antiproliferative Effect ofLife (Basel, Switzerland) · 2022Article
- Safety studies of Nexrutine, bark extract ofHeliyon · 2021Article
- Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.PloS one · 2019Article
- Effects of exogenous 6-BA and NAA on growth and contents of medicinal ingredient ofSaudi journal of biological sciences · 2018Article
- Screening the active compounds of Phellodendri Amurensis cortex for treating prostate cancer by high-throughput chinmedomics.Scientific reports · 2017Article
- Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.Molecular carcinogenesis · 2017Article
- Food-based natural products for cancer management: Is the whole greater than the sum of the parts?Seminars in cancer biology · 2016Review
- Extracting the Benefit of NexrutineCurrent pharmacology reports · 2015Article
- Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Phellodendron amurense bark extract (Nexrutine®) has shown a favorable effect on prostate cancer in vivo and in vitro. We evaluated its tolerance in patients undergoing surgery or radiation for prostate cancer. Patients received Nexrutine® orally (500 mg tid) either 1 to 2 months preoperatively or 1 to 2 months prior to and with radiation therapy. Common Terminology Criteria for Adverse Events were used to measure tolerance. In total, 21 patients (9 surgery and 12 radiation) underwent treatment. During the Nexrutine® alone component, there were two transient grade 3 toxicities (hypokalemia and urinary incontinence). There was no grade 4 toxicity. For the combined Nexrutine® and radiation component, no additional patients suffered a grade 3 toxicity. All the toxicities were transient. By the end of the neoadjuvant treatment, 81% of the patients had a decline in prostate-specific antigen. This is the first report of patients with prostate cancer being treated with P. amurense bark extract, and it was very well tolerated. Toxicities were minimal and self-limited. This compound can be safely used in further evaluation of a treatment effect on cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.